{"organizations": [], "uuid": "76254954879884d15ee1018d5f08ecc3aaf58af2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cardurion-pharmaceuticals-licenses/brief-cardurion-pharmaceuticals-licenses-clinical-stage-heart-failure-candidate-from-astellas-idUSFWN1RT0N4", "country": "US", "domain_rank": 408, "title": "BRIEF-Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate From Astellas", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T16:03:00.000+03:00", "replies_count": 0, "uuid": "76254954879884d15ee1018d5f08ecc3aaf58af2"}, "author": "", "url": "https://www.reuters.com/article/brief-cardurion-pharmaceuticals-licenses/brief-cardurion-pharmaceuticals-licenses-clinical-stage-heart-failure-candidate-from-astellas-idUSFWN1RT0N4", "ord_in_thread": 0, "title": "BRIEF-Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate From Astellas", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-cardurion pharmaceuticals licenses clinical", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "astellas pharma inc", "sentiment": "none"}, {"name": "stage heart failure candidate from astellas reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16, 2018 / 1:06 PM / Updated 10 minutes ago BRIEF-Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate From Astellas Reuters Staff \nApril 16 (Reuters) - Astellas Pharma Inc: \n* CARDURION PHARMACEUTICALS LICENSES CLINICAL STAGE HEART FAILURE CANDIDATE FROM ASTELLAS \n* CARDURION PHARMACEUTICALS - ENTERED EXCLUSIVE LICENSING AGREEMENT WITH ASTELLAS TO DEVELOP AND COMMERCIALIZE CRD-733 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-16T16:03:00.000+03:00", "crawled": "2018-04-16T16:23:15.003+03:00", "highlightTitle": ""}